Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab in infants with severe hemophilia A without inhibitors
NL-OMON51172Phase 3Withdrawn
- Sponsor
- Roche
- Start
- Dec 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Roche. Primary endpoints: Treated bleed rate, All bleed rate and 3 more. Planned start Dec 2020; status: withdrawn.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON51172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51172.